Information Provided By:
Fly News Breaks for March 26, 2019
INO
Mar 26, 2019 | 07:23 EDT
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Inovio Pharmaceuticals with an Overweight rating and $12 price target. With the "large and growing" need for non-invasive therapies to treat human papillomavirus-related cervical dysplasia that can also help clear HPV infection, the ongoing Phase 3 Reveal-1/-2 studies are the major value driver for the stock in the next 12-18 months, Duncan tells investors in a research note.
News For INO From the Last 2 Days
There are no results for your query INO